Glycomine Announces $33 Million Series B Financing to Advance its Therapy for a Congenital Disease of Glycosylation
Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced that it has raised $33 million in a Series B financing led by Novo Holdings A/S. Proceeds from the financing will be used to advance